Sees Q1 Revenue of $65M to $80M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 17 2026
0mins
Should l Buy MED?
Sees Q1 revenue $65M-$80M
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MED?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MED
About MED
Medifast, Inc. is a health and wellness company. The Company is engaged in offering habit-based and coach-guided lifestyle solution, OPTAVIA, which provides people with a comprehensive approach to address obesity and support a healthy lifestyle. OPTAVIA provides coaching support along with community, tailored nutrition, and healthy habits, and helps people in their weight-loss journey through each stage of life. Through its collaboration with national virtual primary care provider LifeMD, Inc. and its affiliated medical group, customers have access to GLP-1 medications where clinically appropriate. It sells a variety of weight-loss, weight management and healthy living products all based on its proprietary formulas under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brands. Its product line includes approximately 79 consumable options, including bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medifast Launches OPTAVIA Health System for Insurance Reimbursement
- Insurance Reimbursement Opportunity: Medifast announced that OPTAVIA's comprehensive metabolic health system is now eligible for reimbursement through Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA), allowing clients to save up to 40% on program costs, thereby enhancing accessibility for those prioritizing metabolic health.
- Science-Driven Health Solutions: OPTAVIA combines a science-backed system with coaching to directly address the widespread and often overlooked issue of metabolic dysfunction, with over 90% of U.S. adults classified as metabolically unhealthy, highlighting the urgent market demand for effective solutions.
- Metabolic Synchronization Innovation: Utilizing the science of Metabolic Synchronization™, OPTAVIA not only achieves healthy weight loss but also effectively reduces visceral fat while preserving healthy muscle, aiding clients in restoring metabolic balance and further solidifying Medifast's leadership in the health and wellness sector.
- Future Product Plans: Medifast plans to launch a new system in 2026 featuring clinically studied ingredients designed to further support metabolic health, marking a continued commitment to meeting diverse health journey needs and driving long-term business growth.
See More
Medifast CEO Transition and Q4 2025 Earnings Insights
- CEO Transition Plan: Medifast's Executive Chairman and CEO Daniel Chard announced his resignation effective June 1, 2026, with current President Nick Johnson expected to take over, indicating a structured leadership transition aimed at continuing the company's shift towards metabolic health.
- Financial Performance Overview: Q4 2025 revenue was $75.1 million, a 36.9% year-over-year decline primarily due to a decrease in active coaches, yet average revenue per active coach increased by 6.2%, suggesting improvements in coach productivity that could support future revenue growth.
- New Product Line Development: The company plans to launch a new product line focused on metabolic synchronization in the second half of 2026, aimed at reducing visceral fat and improving body composition, highlighting Medifast's innovation and adaptability in the metabolic health market.
- Future Outlook and Guidance: Management expects Q1 2026 revenue to range from $65 million to $80 million, with full-year guidance of $270 million to $300 million, reflecting confidence in future growth while emphasizing that continued improvements in coach productivity will be a key driver.
See More
Medifast Q4 Earnings Report Analysis
- Disappointing Earnings: Medifast reported a Q4 GAAP EPS of -$1.65, missing expectations by $0.83, indicating significant challenges in profitability that could undermine investor confidence.
- Revenue Decline: The company generated $75.1 million in revenue, a 36.9% year-over-year decrease, although it beat market expectations by $3.7 million; however, the ongoing revenue decline may lead to tighter cash flows and operational stability issues.
- Negative Enterprise Value: Medifast is classified as a net-net company with a negative enterprise value, reflecting market pessimism regarding its future growth potential, which could limit its financing capabilities and strategic investments.
- Cautious Market Reaction: Given the negative trends highlighted in the earnings report, investors may adopt a cautious stance towards Medifast's future performance, further impacting its stock price and market positioning.
See More
Medifast to Announce Q4 Earnings on February 17
- Earnings Announcement: Medifast (MED) is set to release its Q4 2023 earnings on February 17 after market close, with a consensus EPS estimate of -$0.82, reflecting a staggering 920% year-over-year decline, indicating severe profitability challenges for the company.
- Revenue Decline Forecast: Analysts predict that Medifast's revenue will reach $71.4 million, representing a 40% year-over-year decrease, which highlights the challenges the company faces in a competitive market and a weakening consumer demand.
- Historical Performance Review: Over the past two years, Medifast has beaten EPS and revenue estimates 88% of the time, although the current expectations indicate a significant downturn that could impact investor confidence moving forward.
- Enterprise Value Assessment: According to Seeking Alpha's quant rating, Medifast is classified as a net-net company with a negative enterprise value, suggesting a pessimistic outlook on its future profitability, which may lead to further pressure on its stock price.
See More
Doseology Sciences Partners with McKinney to Enhance Regulatory Compliance
- Strategic Partnership: Doseology has formed a strategic partnership with McKinney Regulatory Science Advisors to enhance its regulatory compliance capabilities, ensuring product development meets stringent FDA requirements, thereby accelerating market entry and strengthening competitiveness.
- Market Outlook: The global pouch market is projected to exceed $69.46 billion by 2032, and through its collaboration with McKinney, Doseology aims to secure a leading position in this rapidly growing market, driving the commercialization of its innovative oral products.
- Compliance Advantage: McKinney will provide Doseology with comprehensive regulatory guidance, including PMTA preparation and post-market compliance, ensuring its products gain approval in a complex regulatory environment, thus reducing market access risks.
- Science-Driven Approach: Doseology is committed to a science and innovation-driven strategy, ensuring its products not only meet consumer demands but also gain regulatory recognition, thereby establishing a sustainable business model in a competitive market.
See More
Doseology Sciences Partners with McKinney to Enhance Regulatory Compliance
- Market Potential: The global consumer healthcare market is projected to reach $362.17 billion by 2026, and Doseology is enhancing its regulatory compliance capabilities through a partnership with McKinney Regulatory Science Advisors, thereby strengthening its competitive position in this landscape.
- Strategic Collaboration: The partnership with McKinney will encompass formulation strategy, data generation, and PMTA preparation, ensuring that Doseology's product development is not only innovative but also aligned with regulatory expectations, laying the groundwork for entry into a global pouch market expected to exceed $69.46 billion.
- Clear Regulatory Pathway: McKinney's expert guidance will assist Doseology in expediting market access under FDA requirements while strengthening intellectual property protection through aligned formulation and testing strategies, ensuring its products stand out in a competitive market.
- Leadership Team Enhancement: Doseology has appointed Patrick Sills, a former executive from Swedish Match and Philip Morris International, as its commercial leader, combining a robust regulatory strategy with secured manufacturing infrastructure to propel the company towards market entry, showcasing strong growth potential.
See More
Medifast Launches OPTAVIA Health System for Insurance Reimbursement
- Insurance Reimbursement Opportunity: Medifast announced that OPTAVIA's comprehensive metabolic health system is now eligible for reimbursement through Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA), allowing clients to save up to 40% on program costs, thereby enhancing accessibility for those prioritizing metabolic health.
- Science-Driven Health Solutions: OPTAVIA combines a science-backed system with coaching to directly address the widespread and often overlooked issue of metabolic dysfunction, with over 90% of U.S. adults classified as metabolically unhealthy, highlighting the urgent market demand for effective solutions.
- Metabolic Synchronization Innovation: Utilizing the science of Metabolic Synchronization™, OPTAVIA not only achieves healthy weight loss but also effectively reduces visceral fat while preserving healthy muscle, aiding clients in restoring metabolic balance and further solidifying Medifast's leadership in the health and wellness sector.
- Future Product Plans: Medifast plans to launch a new system in 2026 featuring clinically studied ingredients designed to further support metabolic health, marking a continued commitment to meeting diverse health journey needs and driving long-term business growth.
See More
Medifast CEO Transition and Q4 2025 Earnings Insights
- CEO Transition Plan: Medifast's Executive Chairman and CEO Daniel Chard announced his resignation effective June 1, 2026, with current President Nick Johnson expected to take over, indicating a structured leadership transition aimed at continuing the company's shift towards metabolic health.
- Financial Performance Overview: Q4 2025 revenue was $75.1 million, a 36.9% year-over-year decline primarily due to a decrease in active coaches, yet average revenue per active coach increased by 6.2%, suggesting improvements in coach productivity that could support future revenue growth.
- New Product Line Development: The company plans to launch a new product line focused on metabolic synchronization in the second half of 2026, aimed at reducing visceral fat and improving body composition, highlighting Medifast's innovation and adaptability in the metabolic health market.
- Future Outlook and Guidance: Management expects Q1 2026 revenue to range from $65 million to $80 million, with full-year guidance of $270 million to $300 million, reflecting confidence in future growth while emphasizing that continued improvements in coach productivity will be a key driver.
See More
Medifast Q4 Earnings Report Analysis
- Disappointing Earnings: Medifast reported a Q4 GAAP EPS of -$1.65, missing expectations by $0.83, indicating significant challenges in profitability that could undermine investor confidence.
- Revenue Decline: The company generated $75.1 million in revenue, a 36.9% year-over-year decrease, although it beat market expectations by $3.7 million; however, the ongoing revenue decline may lead to tighter cash flows and operational stability issues.
- Negative Enterprise Value: Medifast is classified as a net-net company with a negative enterprise value, reflecting market pessimism regarding its future growth potential, which could limit its financing capabilities and strategic investments.
- Cautious Market Reaction: Given the negative trends highlighted in the earnings report, investors may adopt a cautious stance towards Medifast's future performance, further impacting its stock price and market positioning.
See More
Medifast to Announce Q4 Earnings on February 17
- Earnings Announcement: Medifast (MED) is set to release its Q4 2023 earnings on February 17 after market close, with a consensus EPS estimate of -$0.82, reflecting a staggering 920% year-over-year decline, indicating severe profitability challenges for the company.
- Revenue Decline Forecast: Analysts predict that Medifast's revenue will reach $71.4 million, representing a 40% year-over-year decrease, which highlights the challenges the company faces in a competitive market and a weakening consumer demand.
- Historical Performance Review: Over the past two years, Medifast has beaten EPS and revenue estimates 88% of the time, although the current expectations indicate a significant downturn that could impact investor confidence moving forward.
- Enterprise Value Assessment: According to Seeking Alpha's quant rating, Medifast is classified as a net-net company with a negative enterprise value, suggesting a pessimistic outlook on its future profitability, which may lead to further pressure on its stock price.
See More
Doseology Sciences Partners with McKinney to Enhance Regulatory Compliance
- Strategic Partnership: Doseology has formed a strategic partnership with McKinney Regulatory Science Advisors to enhance its regulatory compliance capabilities, ensuring product development meets stringent FDA requirements, thereby accelerating market entry and strengthening competitiveness.
- Market Outlook: The global pouch market is projected to exceed $69.46 billion by 2032, and through its collaboration with McKinney, Doseology aims to secure a leading position in this rapidly growing market, driving the commercialization of its innovative oral products.
- Compliance Advantage: McKinney will provide Doseology with comprehensive regulatory guidance, including PMTA preparation and post-market compliance, ensuring its products gain approval in a complex regulatory environment, thus reducing market access risks.
- Science-Driven Approach: Doseology is committed to a science and innovation-driven strategy, ensuring its products not only meet consumer demands but also gain regulatory recognition, thereby establishing a sustainable business model in a competitive market.
See More
Doseology Sciences Partners with McKinney to Enhance Regulatory Compliance
- Market Potential: The global consumer healthcare market is projected to reach $362.17 billion by 2026, and Doseology is enhancing its regulatory compliance capabilities through a partnership with McKinney Regulatory Science Advisors, thereby strengthening its competitive position in this landscape.
- Strategic Collaboration: The partnership with McKinney will encompass formulation strategy, data generation, and PMTA preparation, ensuring that Doseology's product development is not only innovative but also aligned with regulatory expectations, laying the groundwork for entry into a global pouch market expected to exceed $69.46 billion.
- Clear Regulatory Pathway: McKinney's expert guidance will assist Doseology in expediting market access under FDA requirements while strengthening intellectual property protection through aligned formulation and testing strategies, ensuring its products stand out in a competitive market.
- Leadership Team Enhancement: Doseology has appointed Patrick Sills, a former executive from Swedish Match and Philip Morris International, as its commercial leader, combining a robust regulatory strategy with secured manufacturing infrastructure to propel the company towards market entry, showcasing strong growth potential.
See More
